Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.55
SCMP's Cash to Debt is ranked lower than
75% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.45 vs. SCMP: 0.55 )
Ranked among companies with meaningful Cash to Debt only.
SCMP' s Cash to Debt Range Over the Past 10 Years
Min: 0.43  Med: 9999.00 Max: No Debt
Current: 0.55
Equity to Asset 0.23
SCMP's Equity to Asset is ranked lower than
92% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. SCMP: 0.23 )
Ranked among companies with meaningful Equity to Asset only.
SCMP' s Equity to Asset Range Over the Past 10 Years
Min: -0.21  Med: 0.50 Max: 0.82
Current: 0.23
-0.21
0.82
Interest Coverage 2.67
SCMP's Interest Coverage is ranked lower than
85% of the 467 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.06 vs. SCMP: 2.67 )
Ranked among companies with meaningful Interest Coverage only.
SCMP' s Interest Coverage Range Over the Past 10 Years
Min: 3.55  Med: 90.98 Max: 9999.99
Current: 2.67
3.55
9999.99
F-Score: 6
Z-Score: 2.09
M-Score: -1.49
WACC vs ROIC
12.33%
28.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 20.07
SCMP's Operating margin (%) is ranked higher than
82% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. SCMP: 20.07 )
Ranked among companies with meaningful Operating margin (%) only.
SCMP' s Operating margin (%) Range Over the Past 10 Years
Min: -32.3  Med: 15.15 Max: 29.02
Current: 20.07
-32.3
29.02
Net-margin (%) 13.40
SCMP's Net-margin (%) is ranked higher than
75% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.15 vs. SCMP: 13.40 )
Ranked among companies with meaningful Net-margin (%) only.
SCMP' s Net-margin (%) Range Over the Past 10 Years
Min: -31.6  Med: 9.27 Max: 41.39
Current: 13.4
-31.6
41.39
ROE (%) 22.64
SCMP's ROE (%) is ranked higher than
87% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. SCMP: 22.64 )
Ranked among companies with meaningful ROE (%) only.
SCMP' s ROE (%) Range Over the Past 10 Years
Min: -37.45  Med: 15.59 Max: 154.11
Current: 22.64
-37.45
154.11
ROA (%) 8.24
SCMP's ROA (%) is ranked higher than
72% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.76 vs. SCMP: 8.24 )
Ranked among companies with meaningful ROA (%) only.
SCMP' s ROA (%) Range Over the Past 10 Years
Min: -11.28  Med: 7.14 Max: 37.89
Current: 8.24
-11.28
37.89
ROC (Joel Greenblatt) (%) 105.57
SCMP's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.16 vs. SCMP: 105.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SCMP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -138.06  Med: 100.40 Max: 6536.15
Current: 105.57
-138.06
6536.15
Revenue Growth (3Y)(%) 19.80
SCMP's Revenue Growth (3Y)(%) is ranked higher than
84% of the 602 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. SCMP: 19.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SCMP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.2  Med: 19.80 Max: 129.3
Current: 19.8
-21.2
129.3
EBITDA Growth (3Y)(%) 69.00
SCMP's EBITDA Growth (3Y)(%) is ranked higher than
96% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. SCMP: 69.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SCMP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -47  Med: 62.15 Max: 206.8
Current: 69
-47
206.8
» SCMP's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

SCMP Guru Trades in Q2 2015

Joel Greenblatt 334,346 sh (+222.92%)
Jim Simons 334,100 sh (+49.34%)
Paul Tudor Jones 15,209 sh (+15.14%)
» More
Q3 2015

SCMP Guru Trades in Q3 2015

Paul Tudor Jones 46,925 sh (+208.53%)
Jim Simons 442,100 sh (+32.33%)
Joel Greenblatt 156,205 sh (-53.28%)
» More
Q4 2015

SCMP Guru Trades in Q4 2015

Joel Greenblatt 583,716 sh (+273.69%)
Jim Simons 554,800 sh (+25.49%)
Paul Tudor Jones 31,008 sh (-33.92%)
» More
Q1 2016

SCMP Guru Trades in Q1 2016

Chuck Royce 17,459 sh (New)
Jim Simons 825,700 sh (+48.83%)
Paul Tudor Jones 43,846 sh (+41.40%)
Joel Greenblatt 284,704 sh (-51.23%)
» More
» Details

Insider Trades

Latest Guru Trades with SCMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:SZSE:000790, TSX:GUD, SZSE:002728, SZSE:300452, SZSE:000597, NAS:ACET » details
Traded in other countries:R3A.Germany,
Sucampo Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in research & development of proprietary drugs based on ion channel activators known as prostones to treat gastrointestinal, neurologic, & oncology-based inflammatory disorders.

Sucampo Pharmaceuticals Inc was incorporated on 05 December 1996. The Company is a biopharmaceutical company engaged in research, discovery, development and commercialization of proprietary drugs based on ion channel activators known as prostones. The Company is engaged in developing and/or commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and also considering other potential therapeutic applications of its drug technologies. It generates revenue primarily from product royalties, development milestone payments, clinical development activities and product sales. The Company seeks additional regulatory approvals and additional indications for AMITIZA (lubiprostone), RESCULA (unoprostone isopropyl) and other compounds. Its operations are conducted through subsidiaries based in Japan, the United States, Switzerland, the United Kingdom and Luxembourg. Its reportable geographic segments are Asia, the Americas and Europe. The Company has over 525 active issued patents based on its proprietary prostone technology. It holds all commercialization rights for unoprostone isopropyl except for Japan, Korea, Taiwan and the People's Republic of China.

Ratios

vs
industry
vs
history
P/E(ttm) 23.50
SCMP's P/E(ttm) is ranked higher than
58% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.44 vs. SCMP: 23.50 )
Ranked among companies with meaningful P/E(ttm) only.
SCMP' s P/E(ttm) Range Over the Past 10 Years
Min: 5.44  Med: 25.80 Max: 109.08
Current: 23.5
5.44
109.08
Forward P/E 8.38
SCMP's Forward P/E is ranked higher than
83% of the 90 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.95 vs. SCMP: 8.38 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.50
SCMP's PE(NRI) is ranked higher than
58% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.81 vs. SCMP: 23.50 )
Ranked among companies with meaningful PE(NRI) only.
SCMP' s PE(NRI) Range Over the Past 10 Years
Min: 5.42  Med: 25.64 Max: 105.44
Current: 23.5
5.42
105.44
Price/Owner Earnings (ttm) 10.76
SCMP's Price/Owner Earnings (ttm) is ranked higher than
87% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.19 vs. SCMP: 10.76 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SCMP' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.23  Med: 33.13 Max: 260.44
Current: 10.76
9.23
260.44
P/B 5.28
SCMP's P/B is ranked lower than
76% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. SCMP: 5.28 )
Ranked among companies with meaningful P/B only.
SCMP' s P/B Range Over the Past 10 Years
Min: 0.97  Med: 4.84 Max: 11.83
Current: 5.28
0.97
11.83
P/S 3.07
SCMP's P/S is ranked lower than
54% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. SCMP: 3.07 )
Ranked among companies with meaningful P/S only.
SCMP' s P/S Range Over the Past 10 Years
Min: 1.2  Med: 3.20 Max: 9.54
Current: 3.07
1.2
9.54
PFCF 16.33
SCMP's PFCF is ranked higher than
67% of the 199 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.71 vs. SCMP: 16.33 )
Ranked among companies with meaningful PFCF only.
SCMP' s PFCF Range Over the Past 10 Years
Min: 3.67  Med: 28.00 Max: 376.52
Current: 16.33
3.67
376.52
POCF 13.75
SCMP's POCF is ranked higher than
64% of the 265 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.71 vs. SCMP: 13.75 )
Ranked among companies with meaningful POCF only.
SCMP' s POCF Range Over the Past 10 Years
Min: 3.62  Med: 28.42 Max: 161.87
Current: 13.75
3.62
161.87
EV-to-EBIT 15.99
SCMP's EV-to-EBIT is ranked higher than
64% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.64 vs. SCMP: 15.99 )
Ranked among companies with meaningful EV-to-EBIT only.
SCMP' s EV-to-EBIT Range Over the Past 10 Years
Min: -2724.9  Med: 9.80 Max: 51.3
Current: 15.99
-2724.9
51.3
EV-to-EBITDA 9.74
SCMP's EV-to-EBITDA is ranked higher than
77% of the 569 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.81 vs. SCMP: 9.74 )
Ranked among companies with meaningful EV-to-EBITDA only.
SCMP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -746  Med: 10.10 Max: 193.6
Current: 9.74
-746
193.6
Shiller P/E 49.86
SCMP's Shiller P/E is ranked lower than
55% of the 146 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 46.77 vs. SCMP: 49.86 )
Ranked among companies with meaningful Shiller P/E only.
SCMP' s Shiller P/E Range Over the Past 10 Years
Min: 17.34  Med: 44.77 Max: 107.31
Current: 49.86
17.34
107.31
Current Ratio 3.65
SCMP's Current Ratio is ranked higher than
67% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. SCMP: 3.65 )
Ranked among companies with meaningful Current Ratio only.
SCMP' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.60 Max: 9.21
Current: 3.65
1.27
9.21
Quick Ratio 3.26
SCMP's Quick Ratio is ranked higher than
69% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.87 vs. SCMP: 3.26 )
Ranked among companies with meaningful Quick Ratio only.
SCMP' s Quick Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.57 Max: 9.21
Current: 3.26
1.27
9.21
Days Inventory 79.13
SCMP's Days Inventory is ranked higher than
70% of the 668 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. SCMP: 79.13 )
Ranked among companies with meaningful Days Inventory only.
SCMP' s Days Inventory Range Over the Past 10 Years
Min: 2.34  Med: 3.08 Max: 164.56
Current: 79.13
2.34
164.56
Days Sales Outstanding 34.33
SCMP's Days Sales Outstanding is ranked higher than
84% of the 620 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.15 vs. SCMP: 34.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCMP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.75  Med: 13.77 Max: 54.23
Current: 34.33
1.75
54.23
Days Payable 34.74
SCMP's Days Payable is ranked lower than
82% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.47 vs. SCMP: 34.74 )
Ranked among companies with meaningful Days Payable only.
SCMP' s Days Payable Range Over the Past 10 Years
Min: 9.38  Med: 70.01 Max: 224.09
Current: 34.74
9.38
224.09

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.53
SCMP's Price/Projected FCF is ranked higher than
50% of the 311 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. SCMP: 2.53 )
Ranked among companies with meaningful Price/Projected FCF only.
SCMP' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.93  Med: 3.59 Max: 46
Current: 2.53
0.93
46
Price/Median PS Value 0.97
SCMP's Price/Median PS Value is ranked higher than
64% of the 680 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. SCMP: 0.97 )
Ranked among companies with meaningful Price/Median PS Value only.
SCMP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.01 Max: 2.45
Current: 0.97
0.67
2.45
Earnings Yield (Greenblatt) (%) 6.26
SCMP's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. SCMP: 6.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SCMP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2  Med: 6.25 Max: 130.1
Current: 6.26
2
130.1

More Statistics

Revenue (TTM) (Mil) $170.9
EPS (TTM) $ 0.50
Beta1.72
Short Percentage of Float8.69%
52-Week Range $9.59 - 29.67
Shares Outstanding (Mil)45.79

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 206 238 259
EPS ($) 0.94 1.41 1.67
EPS without NRI ($) 0.94 1.41 1.67
EPS Growth Rate
(3Y to 5Y Estimate)
97.00%
» More Articles for SCMP

Headlines

Articles On GuruFocus.com
NeoPhotonics Delivers Sustained Profitability; Gevo Continues Biofuel Deal Momentum May 08 2015 
Pharmaceutical Stock Picks For March Mar 04 2015 
Weekly CEO Sells Highlight: VeriFone Systems Inc, Northeast Utilities, Sucampo Pharmaceuticals Inc, Jan 26 2014 
Weekly CEO Sells Highlight: Sucampo Pharmaceuticals Inc, Family Dollar Stores Inc, Nike Inc, Hallibu Oct 21 2013 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 08 2011 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 03 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 06 2009 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
ETF’s with exposure to Sucampo Pharmaceuticals, Inc. : May 19, 2016 May 18 2016
Sucampo Pharmaceuticals, Inc. :SCMP-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016
Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : May... May 17 2016
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2016 UBS Global Healthcare... May 17 2016
SUCAMPO PHARMACEUTICALS, INC. Financials May 13 2016
Sucampo Pharma upgraded by WallachBeth May 05 2016
SUCAMPO PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report May 05 2016
Edited Transcript of SCMP earnings conference call or presentation 4-May-16 12:30pm GMT May 04 2016
Sucampo Pharmaceuticals Inc Earnings Call scheduled for 8:30 am ET today May 04 2016
Q1 2016 Sucampo Pharmaceuticals Inc Earnings Release - Before Market Open May 04 2016
Sucampo Reports Strong Results for First Quarter of 2016 May 04 2016
Sucampo reports 1Q loss May 04 2016
Sucampo reports 1Q loss May 04 2016
SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 04 2016
Sucampo Reports Strong Results for First Quarter of 2016 May 04 2016
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of America Merrill Lynch... May 03 2016
CORRECTING and REPLACING Sucampo Standardizes on Veeva Vault for a Single Source of Truth and... Apr 28 2016
Evolent Health awards executive bonuses following debut on NYSE Apr 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)